Rate My Professor Ziad Mallat

Mallat's research centers on immune mechanisms driving cardiovascular inflammation in atherosclerosis, post-ischaemic injury such as myocardial infarction, and aortic aneurysm and dissection. He integrates basic science, preclinical animal models, and translational clinical studies to develop immunomodulatory and vaccination strategies that enhance protective immune responses against cardiovascular diseases. His group has advanced proof-of-concept clinical trials testing immune-modulatory therapies in patients with coronary artery disease. With over 250 peer-reviewed publications, notable works include 'Natural regulatory T cells control the development of atherosclerosis in mice' (Nature Medicine, 2006), 'TGF-beta activity protects against inflammatory aortic aneurysm progression and complications in angiotensin II-infused mice' (Journal of Clinical Investigation, 2010), 'B lymphocytes trigger monocyte mobilization and impair heart function after acute myocardial infarction' (Nature Medicine, 2013), 'APRIL limits atherosclerosis by binding to heparan sulfate proteoglycans' (Nature, 2021), and 'Regulatory T-cell response to low-dose interleukin-2 in ischemic heart disease' (NEJM Evidence, 2021). Mallat serves on the editorial boards of Circulation Research and JCI Insight and is co-editor of Atherosclerosis. His pioneering identification of counter-regulatory immune pathways has influenced vaccination approaches for atherosclerosis and opened new avenues in aneurysm research, earning him the 2025 Louis & Artur Lucian Award for Research in Circulatory Diseases and election as a Fellow of the Academy of Medical Sciences in 2020.